PreveCeutical Medical (TSE:PREV) has released an update.
PreveCeutical Medical has successfully closed a transaction involving the sale of intellectual property assets to its subsidiary, BioGene Therapeutics, for a total of USD$1,353,227. The deal includes a cash payment and the issuance of 16 million common shares of BioGene, with plans to distribute some of these shares to shareholders. This strategic move could potentially enhance PreveCeutical’s financial position and shareholder value.
For further insights into TSE:PREV stock, check out TipRanks’ Stock Analysis page.
Trending Articles
- Deutsche Bank Pounds the Table on Tesla Stock
- ‘Breath of Fresh Air,’ Says Daniel Ives About Rivian Stock
- ‘It’s Not Too Late to Load Up,’ Says Analyst About Nvidia Stock
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
